CHSU Discovery

Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis.

Cardiology research
volume 12 issue 2 pages 98-108
4/21/2021
DOI: 10.14740/cr1224 PMID: 33738013
ISSN: 1923-2829 EISSN: 1923-2837 KBID: 681046 LN: Parihar CHSU: Faculty
  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935639/
  2. https://pubmed.ncbi.nlm.nih.gov/33738013
  3. https://doi.org/10.14740/cr1224

Repository

Articles

Description

Background

Adding ezetimibe to high-intensity statin therapy is used for additional lowering of low-density lipoprotein cholesterol (LDL-C); however, there are little data on the efficacy of ezetimibe when combined with a high-intensity statin. A meta-analysis was performed to evaluate the efficacy of ezetimibe added to high-intensity statin therapy on LDL-C levels.

Methods

A literature search from database inception to May 2020 was performed using PubMed, EMBASE and Cochrane Central Register of Controlled Trials. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used in this meta-analysis, in which the random-effects model was adopted for the calculation of the mean difference (MD). The Cochrane Collaboration’s tool for assessing the risk of bias was used to evaluate the quality of the included trials.

Results

A total of 14 trials with 2,007 patients were included in this study. Compared to the high-intensity statin monotherapy, the MD in LDL-C reduction with high-intensity statin therapy plus ezetimibe was -14.00% (95% confidence interval: -17.78 to -10.22; P < 0.001) with a moderate degree of heterogeneity (P < 0.001, I 2 = 66%). No significant publication bias among the included trials was identified.

Conclusions

Our study found that adding ezetimibe to high-intensity statin therapy provided a significant but attenuated incremental reduction in LDL-C levels. Whether the magnitude of this additional lowering of LDL-C levels would lead to benefits in clinical cardiovascular outcomes needs further investigation.

Show Full Abstract Collapse Abstract

Subjects

Affiliations

  1. College of Pharmacy, California Health Sciences University, Clovis, CA, USA
  2. School of Pharmacy, Philadelphia College of Osteopathic Medicine, Suwanee, GA, USA
  3. The Heart Center of Northeast Georgia Medical Center, Gainesville, GA, USA

Publisher

Elmer Press (Canada)

Languages

English

Citations

  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation (2019). , 139(25), e1082.
    View full text
  • Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. Int J Cardiol (2020). , 303, 8.
    View full text
  • Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015). , 372(25), 2387.
    View full text
  • Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin (2007). , 23(8), 2009.
    View full text
  • Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: Systematic review and meta-analysis. Curr Med Res Opin (2011). , 27(6), 1191.
    View full text
  • Safety and efficacy of ezetimibe: A meta-analysis. Int J Cardiol (2015). , 201, 247.
    View full text
  • Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: A meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther (2012). , 17(4), 357.
    View full text
  • Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: A meta-analysis of literature. Lipids Health Dis (2020). , 19(1), 1.
    View full text
  • Ezetimibe in high-risk, previously treated statin patients: A systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol (2019). , 108(5), 487.
    View full text
  • A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014). , 370(19), 1809.
    View full text
  • Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis (2016). , 244, 138.
    View full text
  • Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis (2017). , 261, 12.
    View full text
  • Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. JAMA (2014). , 311(18), 1870.
    View full text
  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation (2019). , 139(25), e1046.
    View full text
  • Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am J Cardiol (2011). , 107(11), 1571.
    View full text
  • Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation (2003). , 107(19), 2409.
    View full text
  • Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol (2007). , 99(5), 673.
    View full text
  • Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sci (2013). , 92(14-16), 845.
    View full text
  • A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther (2018). , 40(2), 226.
    View full text
  • Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med (2017). , 18(2), 110.
    View full text
  • Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther (2016). , 34(5), 371.
    View full text
  • Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther (2018). , 40(6), 993.
    View full text
  • Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys (2014). , 70(1), 687.
    View full text
  • Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens. J Clin Lipidol (2015). , 9(4), 542.
    View full text
  • Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clin Ther (2017). , 39(1), 107.
    View full text
  • Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008). , 358(14), 1431.
    View full text
  • Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol (2008). , 102(11), 1495.
    View full text
  • A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc (2005). , 80(5), 587.
    View full text
  • Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis (2012). , 223(2), 251.
    View full text
  • Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015). , 385(9976), 1397.
    View full text
  • Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA (2016). , 316(12), 1289.
    View full text
  • Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA (2018). , 319(15), 1566.
    View full text
Show all 32 citations
Loading...

Confirm

Alert

Place a hold

Log in